Clinical performance is complex and often involves multi-systematic stress. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can help connect teams of authoritative experts at home and abroad to provide accurate diagnostic and therapeutic programs. Treatment for and management of congenital carnitine deficiency with low carnitine needs to be individualized, often including multidimensional management, including drug therapy, rehabilitation interventions, regular follow-up, and more. In recent years, with the development of targeted therapy, immune regulation therapy, and precision medicine, many previously difficult-to-treat genetic metabolic diseases have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored during treatment and timely adjusted according to changing conditions. Multidisciplinary collaboration (MDT) is particularly important for the overall management of congenital carnitine deficiency with congenital carnitine deficiency. The platform serves the China International Medical Service System, which combines national and international teams of authoritative experts in the field of genetic metabolism to provide the following services to patients: 1.
Remote pre-diagnosis: pre-examination of medical history, precise diagnostic directions and medical advice by a team of experts; 2. Chinese interviews: arranging face-to-face diagnosis with authoritative experts, developing personalized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects. Support for remote pre-diagnosis, visiting interviews, full translation and escort.